Patient - PACT
New Clinical Trial and Research

Trial title	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Trial synopsis	The purpose of the Spirit study is to evaluate the safety, potential effectiveness, and tolerability of an investigational drug called BG00011 as a potential treatment for people with IPF. If you qualify for the study, participation will last about 65 weeks and include around 14 visits to the study site. You may also be asked to come in for additional, unscheduled study visit any time you have an IPF exacerbation. You will be assigned by chance (like flipping a coin) to receive either BG00011 or placebo. Placebo looks like BG00011, but contains no active ingredients. Neither you or your study staff with know whether you are receiving BG00011 or placebo, but your study can get this information if needed for medical reasons. You will take a dose of BG00011 or placebo for 52 weeks. Eight weeks after your last dose, you will have your final follow-up visit to the study site.
Investigational medicinal product, comparator and randomisation	Participants will receive BG00011 56 mg once weekly by subcutaneous (SC) injection for 52 weeks vs Placebo
Disease target	Idiopathic Pulmonary Fibrosis
Sponsor	Biogen
Duration	Up to 65 weeks
Trial Status	Study completed
Lead site(s) in Australia	The Prince Charles Hospital, Lung Research Qld
Lead site(s) in New Zealand	N/A
Additional sites	St Vincent's Hospital, NSW The Alfred Hospital, VIC John Hunter Hospital, NSW Princess Alexandra Hospital, Qld Frankston Hospital, VIC Royal Prince Alfred Hospital, NSW Fiona Stanley Hospital, WA Royal Adelaide, SA Institute of Breathing and Sleeping (Austin Hospital), VIC Trials West, WA

Contact	pactcoordinator@cre-pf.org.au